Clinical Trial Update: Humanized Anti-CD25 Antibody for Prophylaxis of aGVHD in Elderly Underwent HID-HSCT [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating a humanized anti-CD25 antibody for prophylaxis of acute graft-versus-host disease in elderly patients after haploidenti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Humanized anti-CD25 antibody (anti-CD25 antibody)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT | Phase 2 | Status: UNKNOWN